Comparison of Diagnostic Performances between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting

Na Yeon Jung, Eun Soo Kim, Hyang Sook Kim, Sumin Jeon, Myung Jun Lee, Kyoungjune Pak, Jae Hyeok Lee, Young Min Lee, Kangyoon Lee, Jin Hong Shin, Jun Kyeung Ko, Jae Meen Lee, Jin A. Yoon, Chungsu Hwang, Kyung Un Choi, Eun Chong Lee, Joon Kyung Seong, Gi Yeong Huh, Dae Seong Kim, Eun Joo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The diagnostic performances of cerebrospinal fluid (CSF) biomarkers and amyloid positron emission tomography (PET) were compared by examining the association and concordance or discordance between CSF Aβ1-42 and amyloid PET, after determining our own cut-off values for CSF Alzheimer's disease (AD) biomarkers. Furthermore, we evaluated the ability of CSF biomarkers and amyloid PET to predict clinical progression. CSF Aβ1-42, t-tau, and p-tau levels were analyzed in 203 individuals [27 normal controls, 38 mild cognitive impairment (MCI), 62 AD dementia, and 76 patients with other neurodegenerative diseases] consecutively recruited from two dementia clinics. We used both visual and standardized uptake value ratio (SUVR)-based amyloid PET assessments for analyses. The association of CSF biomarkers with amyloid PET SUVR, hippocampal atrophy, and cognitive function were investigated by linear regression analysis, and the risk of conversion from MCI to AD dementia was assessed using a Cox proportional hazards model. CSF p-tau/Aβ1-42 and t-tau/Aβ1-42 exhibited the best diagnostic accuracies among the CSF AD biomarkers examined. Correlations were observed between CSF biomarkers and global SUVR, hippocampal volume, and cognitive function. Overall concordance and discordance between CSF Aβ1-42 and amyloid PET was 77% and 23%, respectively. Baseline positive CSF Aβ1-42 for MCI demonstrated a 5.6-fold greater conversion risk than negative CSF Aβ1-42. However, amyloid PET findings failed to exhibit significant prognostic value. Therefore, despite presence of a significant correlation between the CSF Aβ1-42 level and SUVR of amyloid PET, and a relevant concordance between CSF Aβ1-42 and amyloid PET, baseline CSF Aβ1-42 better predicted AD conversion.

Original languageEnglish
Pages (from-to)473-490
Number of pages18
JournalJournal of Alzheimer's Disease
Volume74
Issue number2
DOIs
Publication statusPublished - 2020 Jan 1

Keywords

  • Alzheimer disease
  • amyloid
  • cerebrospinal fluid
  • mild cognitive impairment
  • positron emission tomography
  • tau

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Comparison of Diagnostic Performances between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting'. Together they form a unique fingerprint.

  • Cite this

    Jung, N. Y., Kim, E. S., Kim, H. S., Jeon, S., Lee, M. J., Pak, K., Lee, J. H., Lee, Y. M., Lee, K., Shin, J. H., Ko, J. K., Lee, J. M., Yoon, J. A., Hwang, C., Choi, K. U., Lee, E. C., Seong, J. K., Huh, G. Y., Kim, D. S., & Kim, E. J. (2020). Comparison of Diagnostic Performances between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting. Journal of Alzheimer's Disease, 74(2), 473-490. https://doi.org/10.3233/JAD-191109